GLP-5: the quintuple agonist.

The peptide community has started calling it "GLP-5." The actual research name is a mouthful — but the concept is genuinely new: a single molecule that activates five different receptors at once. Published in Nature in April, still in mice. Here is what we know so far.

What people are actually talking about

The technical name of this compound is GLP-1–GIP–Lanifibranor, sometimes shortened to GLP-1–GIP–Lani. Within peptide communities, people have started shorthand-ing it as "GLP-5" — because it activates 5 receptors in one molecule, and that is much easier to say.

So if you have been hearing about "GLP-5" lately and could not find anything official by that name, you are not crazy. It is community shorthand for a compound that is so new it does not have a marketing name yet — it has only existed in published form since April 2026.

One molecule, five receptors

To appreciate why this is interesting, it helps to look at the progression:

• Semaglutide hits 1 receptor (GLP-1).
• Tirzepatide hits 2 receptors (GLP-1 and GIP).
• Retatrutide hits 3 receptors (GLP-1, GIP, and glucagon).
• "GLP-5" / GLP-1–GIP–Lani hits 5 receptors (GLP-1, GIP, PPAR-alpha, PPAR-gamma, PPAR-delta).

The pattern is clear: researchers are stacking more and more targets into single molecules, on the theory that hitting multiple metabolic pathways at the same time produces stronger and more well-rounded effects than hitting any one pathway alone.

The "Trojan horse" design

Here is where the science gets clever. GLP-5 is not just a peptide. It is a peptide-drug conjugate — a hybrid molecule built in two parts.

The peptide part is a GLP-1/GIP dual agonist (similar in concept to tirzepatide). Attached to that peptide via a pH-sensitive chemical linker is a small molecule called lanifibranor, which on its own already activates all three PPAR receptors (alpha, gamma, and delta).

When the conjugate enters the body, the peptide binds to GLP-1 and GIP receptors on metabolic cells. The cell internalizes it. Inside the cell, the slightly acidic environment cleaves the linker, releasing the lanifibranor portion to travel into the cell nucleus and activate the PPARs from within.

The peptide essentially acts as a delivery vehicle, getting the PPAR agonist directly into the cells that matter for metabolic disease. Outside those cells, the lanifibranor stays attached and inactive — which is part of why the researchers hope this design may avoid some of the off-target effects of giving lanifibranor on its own.

What the research showed in mice

In diet-induced obese mice, GLP-5 produced effects that exceeded what GLP-1/GIP dual agonism alone could achieve. Researchers reported elimination of obesity and insulin resistance in the animal model, along with combined improvements in body weight, blood glucose, lipid profile, and inflammation markers.

When the same researchers genetically knocked out the GLP-1, GIP, or PPAR-delta receptors in the mice, the metabolic effects were blunted or vanished — confirming that the molecule actually relies on all of its targets working together, not just one of them dominating.

Why the lineage matters

One reason this compound is worth paying attention to: the lab behind it. The Müller group at Helmholtz Munich, working with researchers at Indiana Biosciences and Novo Nordisk's Indianapolis research center, has a track record. Members of this same intellectual circle developed the conceptual basis for tirzepatide more than a decade ago. The peptide-drug-conjugate platform that underpins GLP-5 was itself published by this group in 2022.

That does not guarantee GLP-5 will reach the clinic — most preclinical compounds do not. But it does mean this is not a fringe project. It is mainstream metabolic research from a serious lab with a history of translating concepts into actual drugs.

Where this fits in the bigger picture

GLP-5 is part of a much broader trend toward poly-agonism in metabolic medicine — combining more and more targets in single molecules. Eli Lilly is reportedly developing a separate quintuple agonist that takes a different angle entirely, combining GLP-1, GIP, glucagon, amylin, and calcitonin receptors instead of incretin-plus-PPARs.

There may eventually be many "5-receptor peptides" by different companies, each taking different combinations of targets. What ties them together is the underlying bet: that targeting multiple metabolic pathways at once produces better results than any single mechanism alone.

For now, GLP-5 (GLP-1–GIP–Lani) is the first published unimolecular quintuple agonist of this kind. It is years away from any clinical availability, but worth knowing about because the science it represents is genuinely a step forward from what came before — and because the conversation around it is going to keep growing.

Putting it in context

If you want to understand where GLP-5 fits, the easiest path is to start with what came before. The blog post on tirzepatide covers the dual-agonist concept that GLP-5 builds on. The calculator and peptide library handle the practical math and dosing for the compounds that actually exist today.

GLP-5 is not something you can order, dose, or use. It is currently a research compound studied only in mice. The point of writing about it now is awareness — so that when the human trial data starts appearing in the next few years, you already understand what is being measured and why it matters.